Ancon Medical NBT detects tuberculosis biomarkers

Blookmington, MN, February 20, 2015 -- Medical device company Ancon Medical Inc. has confirmed today that it has detected Tuberclosis biomarkers using its revolutionary new breath screening technology NBT-GC that makes it possible to easily find the indicators for deadly and dangerous diseases such as TB at their earliest stages. The potential benefits of the Nanoparticle Biomarker Tagging (NBT) technology are far ranging, from conducting mass screenings for contagious diseases, to identifying Lung Cancer and Tuberculosis.